The TAPAS catheter is an innovative system featuring two compliant occlusion balloons enabling targeted local delivery of any physician-specified agent. A unique feature of the device is the ability to adjust the treatment zone up to 300mm, allowing for the treatment of long vessels with only one device and, in certain cases, multiple lesions with one device. The medication can be aspirated out of the catheter after treatment, providing localized intravascular treatment without systemic run-off. The TAPAS catheter can be used in conjunction with Spectranetics laser atherectomy or other interventional devices. Clinical studies are currently underway to investigate whether debulking with laser or other atherectomy devices prior to drug delivery improves patient outcomes.
"I am very excited to begin working with the new TAPAS catheter," said Dr. Lawrence Garcia, St. Elizabeths Medical Center in Boston. "Endovascular treatment is becoming an increasingly targeted therapy approach for our patients. We currently do not have a device that can provide local drug delivery while minimizing systemic effects and be adaptable to a wide variety of patients and anatomies. Although we are years away from the availability of other targeted therapeutic and diagnostic delivery systems in the United States, the TAPAS catheter provides an opportunity for local drug delivery for our patient needs now."
The first procedures were performed by Dr. Eric Dippel at Trinity Medical Center in Bettendorf, Iowa. "The TAPAS catheter provides a flexible platform for a variety of applications," said Dr. Dippel. "I was able to use the product to deliver different drugs tailored to the patients clinical situations."
Scott Drake, President and Chief Executive Officer of Spectranetics, stated, "The TAPAS catheter is a novel approach to delivering therapeutic agents to the peripheral vasculature and fits nicely with our portfolio of devices that allow physicians to cross, prepare, and remove stenoses while preserving native vessels. This partnership is an important next step in our continued drive to provide physicians new and innovative solutions that address the challenges of peripheral vascular disease."
"We are happy to be partnering with Spectranetics on this product," said Ron Solar, CEO of ThermopeutiX. "With our innovation and manufacturing combined with their high quality sales and marketing teams, we are enthusiastic about the success of the TAPAS catheter."
Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in 40 countries throughout the world and are used to treat arterial blockages in the heart and legs as well as the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of peripheral and cardiac laser catheters for ablation of occluded arteries above and below the knee and within coronary arteries. The Company also markets aspiration and thrombectomy catheters for the removal of thrombus and support catheters to facilitate crossing of coronary and peripheral arterial blockages.
The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Posted by Sean Fenske, Editor-in-Chief, MDT